Acrotech Biopharma Inc. clinical trials

A subsidiary of Aurobindo Pharma

The registry lists 28 studies whose lead sponsor is Acrotech Biopharma Inc.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.

Studies

Recruiting first, then most recently updated. Showing 28 of 28. All Aurobindo Pharma studies →

• Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic ImpairmentRecruitingNCT07036133Phase 1

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCLActive, not recruitingNCT06072131Phase 3

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 GenotypesCompletedNCT02680795Phase 1

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)CompletedNCT05608343Phase 3

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic DermatitisCompletedNCT05571943Phase 3

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat TrialsCompletedNCT04184869Phase 1

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)CompletedNCT02594267Phase 1

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous TransplantationCompletedNCT01660633Phase 2

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant PatientsStatus unknownNCT04243434Phase 1

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®WithdrawnNCT01820091Phase 1

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving FolotynWithdrawnNCT01789723Phase 1

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory CancerCompletedNCT01222780Phase 1

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment RegistryCompletedNCT01110733

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Study of Pralatrexate in Female Patients With Previously-treated Breast CancerCompletedNCT01118624Phase 2

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative MalignanciesCompletedNCT00481871Phase 1/2

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLCCompletedNCT01310244Phase 1/2

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell LymphomaCompletedNCT00554827Phase 1

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced CancerCompletedNCT01583777Phase 1

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHLCompletedNCT01851551Phase 1/2

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)CompletedNCT01839097Phase 1

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell LymphomaCompletedNCT00364923Phase 2

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell LymphomaCompletedNCT01134341Phase 1

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous TransplantationCompletedNCT00925782Phase 2

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary BladderCompletedNCT00722553Phase 2

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT00144963Phase 1/2

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic DysfunctionCompletedNCT00145041Phase 1

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.TerminatedNCT02679131Phase 1

  Sponsor listed in the registry: Acrotech Biopharma Inc.

• Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological MalignanciesCompletedNCT02106650Phase 2

  Sponsor listed in the registry: Acrotech Biopharma Inc.